Cathepsin L in human meningiomas

Radiology and Oncology

Volumn 37, Issue 2, 2003, Pages

  Trinkaus, Miha ^a   Vranič, Andrej ^b   Dolenc, Vincenc V ^b   Lah, Tamara T ^a  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cathepsin L; Meningioma pathology; Neoplasm invasiveness; Reverse transcriptase, polymerase chain reaction

Indexed keywords

CATHEPSIN L;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MENINGIOMA; NORTHERN BLOTTING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; STATISTICAL SIGNIFICANCE;

EID: 0038166887     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningeal tumors. In: Kleihaus P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: IARC press; 2000. p. 175-84.
2. Kleihues P, Burger PC, Scheithauer BWm, editors. Histological typing of tumours of the central nervous system. New York,: Springer-Verlag; 1993, pp 33-40.
3. Gottesman MM. Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts. Proc Natl Acad Sci USA 1978; 75: 2767-71.
4. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. SeminCancer Biol 1990; 1: 127-36.
5. Turk B, Turk D, Salvesen GS. Regulating cysteine protease activity: Essential role of protease inhibitors as guardians and regulators. Curr Pharm Design 2002; 8: 1623-37.
6. Portnoy DA, Erickson AH, Kochan J, Ravetch JV, Unkeless JC. Cloning and characterization of a mouse cysteine proteinase. J Biol Chem 1986; 261: 14697-703.
7. Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res 1991; 51: 1478-81.
8. Kos J, Lah T. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep 1998; 5: 1349-61.
9. Lah TI, Čerček M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskal I. Cathepsin B, a prognostic indicator in lymph node negative breast carcinoma patients: comparison with cathepsin D, cathepsin L and other clinical indicators. Clin Cancer Res 2000; 6: 578-84.
10. Levičar N, Strojnik T, Kos J, Dewey AR, Pilkington GJ, Lah TT. Lysosomal enzymes, cathepsins, in brain tumor invasion. J Neuro-Oncol 2002; 58: 21-32.
11. Lah TT, Strojnik T, Levičar N, Bervar A, Zajc I, Pilkington G, Kos J. Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int J Biol Markers 2000; 15: 90-2.
12. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F, Hofler H, Kates RE, Schmitt M. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64.
13. Premzl A, Puizdar V, Zavasnik-Bergant V, Kopitar-Jerala N, Lah TT, Katunuma N, Sloane BF, Turk V, Kos J. Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol Chem 2001; 382: 853-7.
14. Yagel S, Warner AH, Nellans HN, Lala PK, Waghorne C, Denhardt DT. Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. Cancer Res 1989; 49: 3553-7.
15. Katunuma N, Tsuge H, Nukatsuka M, Asao T, Fukushima M. Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastasis of cancer cells. Arch Biochem Biophys 2002, 397; 2: 305-11.
16. Perentes E, Rubinstein LJ. Recent applications of immunoperoxidase histochemistry in human neuro-oncology: An update. Arch Patol Lab Med 1987; 111: 796-812.
17. Arora S, Chauhan SS. Identification and characterization of a novel human cathepsin L splice variant. Gene 2002; 293: 123-31.
18. Perry A, Stafford LS, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53 and DNA flow cytometry in completely resected primary meningiomas. Cancer 2002; 94: 765-72.
19. Nakasu S, Hirano A, Llena JF, Shimra T, Handa J. Interface between the meningioma and the brain. Surg Neurol 1989; 32: 206-12.
20. Strojnik T, Židanik B, Kos J, Lah TT. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 2001, 48: 598-605.
21. Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, Sawaya R, Rao JS. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastas 1996; 14: 27-34.
22. Levičar N, Dewey R, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ, Lah TT. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Therapy 2003; 10: 141-51.
23. Krueger S, Kellner U, Buehling F, et al. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: Effects on the invasive phenotypes. Cancer Gene Therapy 2001; 8: 522-8.
24. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-35.
25. Frosch BA, Sloane BF. The role of proteolytic enzymes in brain tumor invasion. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum MI editors. Brain tumor invasion: Biological, Clinical and Therapeutic Considerations. Wiley-Liss Inc. 1998. p. 275-99.
26. Strojnik T, Kos J, Židanik B, Golouh R, Lah TT. Cathepsin B immunohistochemical staining in tumor and endothelial cells is new prognostic factor in patients with brain tumors. Clin Cancer Res 1999; 5: 559-67.
27. Perret SG, Duthel R, Fotso MJ, Brunon J, Mosnier JF. Stromelysin-3 is expressed by aggresive meningiomas. Cancer 2002; 94: 765-72.
28. Chauhan SS, Popescus NC, Ray D, Fleischmann R, Gottesman MM, Troen BR. Cloning, genomic organisation and chromosomal localisation of human cathepsin L. J Biol Chem 1993: 268, 2: 1039-45.
29. Abudula A, Rommerskirsch W, Weber E, Gunther D, Wiederanders B. Splice variants of human cathepsin L mRNA show different expression rates. Biol Chem 2001; 382: 1583-91.